FR3017298B1 - Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires - Google Patents
Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoiresInfo
- Publication number
- FR3017298B1 FR3017298B1 FR1450956A FR1450956A FR3017298B1 FR 3017298 B1 FR3017298 B1 FR 3017298B1 FR 1450956 A FR1450956 A FR 1450956A FR 1450956 A FR1450956 A FR 1450956A FR 3017298 B1 FR3017298 B1 FR 3017298B1
- Authority
- FR
- France
- Prior art keywords
- conjugates
- pro
- drugs
- cancer
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1450956A FR3017298B1 (fr) | 2014-02-07 | 2014-02-07 | Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires |
| CA2938501A CA2938501C (fr) | 2014-02-07 | 2015-02-06 | Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires |
| ES15709742T ES2843798T3 (es) | 2014-02-07 | 2015-02-06 | Conjugados y profármacos para el tratamiento del cáncer y de enfermedades inflamatorias |
| EP15709742.9A EP3139963B1 (fr) | 2014-02-07 | 2015-02-06 | Conjugués et pro-drogues pour le traitement du cancer et de maladies inflammatoires |
| CN201580018638.0A CN106573071A (zh) | 2014-02-07 | 2015-02-06 | 用于治疗癌症和炎症性疾病的偶联物和前药 |
| JP2016550736A JP6721512B2 (ja) | 2014-02-07 | 2015-02-06 | がん及び炎症性疾患の治療のための結合体及びプロドラッグ |
| DK15709742.9T DK3139963T3 (da) | 2014-02-07 | 2015-02-06 | Konjugater og prodrugs til behandling af cancer og inflammatoriske sygdomme |
| EP20192895.9A EP3766510A1 (fr) | 2014-02-07 | 2015-02-06 | Conjugués et pro-drogues pour le traitement du cancer et de maladies inflammatoires |
| US15/117,069 US10293021B2 (en) | 2014-02-07 | 2015-02-06 | Conjugates and prodrugs for treating cancer and inflammatory diseases |
| CN202210334259.4A CN114917358A (zh) | 2014-02-07 | 2015-02-06 | 用于治疗癌症和炎症性疾病的偶联物和前药 |
| PCT/IB2015/050914 WO2015118497A1 (fr) | 2014-02-07 | 2015-02-06 | Conjugués et pro-drogues pour le traitement du cancer et de maladies inflammatoires |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1450956A FR3017298B1 (fr) | 2014-02-07 | 2014-02-07 | Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR3017298A1 FR3017298A1 (fr) | 2015-08-14 |
| FR3017298B1 true FR3017298B1 (fr) | 2016-03-04 |
Family
ID=50829100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR1450956A Expired - Fee Related FR3017298B1 (fr) | 2014-02-07 | 2014-02-07 | Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10293021B2 (https=) |
| EP (2) | EP3766510A1 (https=) |
| JP (1) | JP6721512B2 (https=) |
| CN (2) | CN114917358A (https=) |
| CA (1) | CA2938501C (https=) |
| DK (1) | DK3139963T3 (https=) |
| ES (1) | ES2843798T3 (https=) |
| FR (1) | FR3017298B1 (https=) |
| WO (1) | WO2015118497A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11384104B2 (en) | 2015-06-19 | 2022-07-12 | Centurion Biopharma Corporation | Delivery systems for controlled drug release |
| WO2017058808A1 (en) * | 2015-10-02 | 2017-04-06 | Sirenas Llc | Anti-cancer compounds and conjugates thereof |
| ES2948846T3 (es) * | 2016-03-29 | 2023-09-20 | Toray Industries | Derivado peptídico y uso del mismo |
| EP3624854B1 (en) | 2017-05-16 | 2026-04-15 | Université de Strasbourg | Protein-drug conjugates and their use in the treatment of cancers |
| CN111712511B (zh) * | 2017-11-30 | 2024-07-16 | 拉德克斯公司 | 澳瑞他汀e衍生物的白蛋白结合产物 |
| CA3095146A1 (en) * | 2018-04-03 | 2019-10-10 | Syndivia | Conjugate of cytotoxic drug and prodrug form of said conjugate |
| EP3965893B1 (en) * | 2019-05-06 | 2025-02-19 | Seekyo | New therapeutic vectors and prodrugs for treating cancers |
| FR3126982B1 (fr) * | 2021-09-14 | 2023-09-15 | Centre Nat Rech Scient | Vecteurs ciblant la beta-d-n-acetylglucosaminidase |
| CN116077674B (zh) * | 2022-12-26 | 2025-03-25 | 北京大学 | 生物分子-聚氮氧化物偶联物及其制备方法与应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1545613T1 (sl) | 2002-07-31 | 2011-11-30 | Seattle Genetics Inc | Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni |
| HUE035853T2 (en) * | 2005-07-18 | 2018-05-28 | Seattle Genetics Inc | Beta-glucuronide-linker-drug conjugates |
| FR2960153B1 (fr) * | 2010-05-20 | 2012-08-17 | Centre Nat Rech Scient | Nouveaux bras autoreactifs et prodrogues les comprenant |
-
2014
- 2014-02-07 FR FR1450956A patent/FR3017298B1/fr not_active Expired - Fee Related
-
2015
- 2015-02-06 CN CN202210334259.4A patent/CN114917358A/zh active Pending
- 2015-02-06 EP EP20192895.9A patent/EP3766510A1/fr active Pending
- 2015-02-06 JP JP2016550736A patent/JP6721512B2/ja active Active
- 2015-02-06 DK DK15709742.9T patent/DK3139963T3/da active
- 2015-02-06 CA CA2938501A patent/CA2938501C/fr active Active
- 2015-02-06 US US15/117,069 patent/US10293021B2/en active Active
- 2015-02-06 WO PCT/IB2015/050914 patent/WO2015118497A1/fr not_active Ceased
- 2015-02-06 ES ES15709742T patent/ES2843798T3/es active Active
- 2015-02-06 EP EP15709742.9A patent/EP3139963B1/fr active Active
- 2015-02-06 CN CN201580018638.0A patent/CN106573071A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3139963B1 (fr) | 2020-10-07 |
| ES2843798T3 (es) | 2021-07-20 |
| DK3139963T3 (da) | 2020-10-26 |
| JP2017506628A (ja) | 2017-03-09 |
| CN114917358A (zh) | 2022-08-19 |
| EP3766510A1 (fr) | 2021-01-20 |
| US10293021B2 (en) | 2019-05-21 |
| CN106573071A (zh) | 2017-04-19 |
| JP6721512B2 (ja) | 2020-07-15 |
| CA2938501A1 (fr) | 2015-08-13 |
| CA2938501C (fr) | 2022-04-05 |
| EP3139963A1 (fr) | 2017-03-15 |
| WO2015118497A1 (fr) | 2015-08-13 |
| FR3017298A1 (fr) | 2015-08-14 |
| US20170095525A1 (en) | 2017-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR22C1011I2 (fr) | Promedicaments de fumarates et leur utilisation pour le traitement de diverses maladies | |
| MA49144A (fr) | Polythérapies pour le traitement du cancer | |
| MA49767A (fr) | Conjugués de cytokine pour le traitement de maladies auto-immunes | |
| EP3448875A4 (en) | COMPOSITIONS FOR TREATING A DISEASE | |
| EP3448987A4 (en) | COMPOSITIONS FOR TREATING A DISEASE | |
| EP3488001A4 (en) | TREATMENT OF CANCER | |
| EP3370703A4 (en) | GEMCABEN COMBINATIONS FOR TREATING HEART CIRCULATION DISEASES | |
| EP3494142A4 (en) | ANTI-SIGLEC-7 ANTIBODIES FOR TREATING CANCER | |
| EP3368559A4 (en) | COMPOSITIONS AND METHODS FOR TREATING CANCER | |
| MA50409A (fr) | Polythérapies pour le traitement du cancer | |
| MA48637A (fr) | Polythérapies pour le traitement du cancer | |
| MA41449A (fr) | Polythérapies pour le traitement de cancers | |
| FR3017298B1 (fr) | Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires | |
| EP3285773A4 (en) | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | |
| PL3169328T3 (pl) | Pochodne chinoliny do leczenia chorób zapalnych | |
| EP2983791A4 (en) | METHOD AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASES | |
| EP3389645A4 (en) | COMBINATIONS FOR TREATING CANCER | |
| EP3359255A4 (en) | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | |
| EP3359192A4 (en) | COMBINATION THERAPY FOR CANCER TREATMENT | |
| EP3373962A4 (en) | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES AND CANCER DISEASES | |
| MA47408A (fr) | Traitement du cancer | |
| EP3630196A4 (en) | COMBINATION THERAPIES FOR TREATMENT OF CANCER | |
| EP3490561A4 (en) | COMBINATIONS FOR TREATING CANCER | |
| EP3383407A4 (en) | CYTARABIN CONJUGATES FOR CANCER THERAPY | |
| EP2967062A4 (en) | DESETHYLHYDROXYCHLOROQUIN FOR THE TREATMENT OF DISEASES RELATED TO INFLAMMATION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PLFP | Fee payment |
Year of fee payment: 2 |
|
| PLFP | Fee payment |
Year of fee payment: 3 |
|
| PLFP | Fee payment |
Year of fee payment: 4 |
|
| PLFP | Fee payment |
Year of fee payment: 5 |
|
| PLFP | Fee payment |
Year of fee payment: 7 |
|
| PLFP | Fee payment |
Year of fee payment: 8 |
|
| ST | Notification of lapse |
Effective date: 20221005 |